| Literature DB >> 28877940 |
Lutfun N Hossain1, Fernando Fernandez-Llimos2, Tim Luckett, Joanna C Moullin3, Desire Durks1, Lucia Franco-Trigo1, Shalom I Benrimoj1, Daniel Sabater-Hernández1,4.
Abstract
OBJECTIVES: The integration of community pharmacy services (CPSs) into primary care practice can be enhanced by assessing (and further addressing) the elements that enable (ie, facilitators) or hinder (ie, barriers) the implementation of such CPSs. These elements have been widely researched from the perspective of pharmacists but not from the perspectives of other stakeholders who can interact with and influence the implementation of CPSs. The aim of this study was to synthesise the literature on patients', general practitioners' (GPs) and nurses' perspectives of CPSs to identify barriers and facilitators to their implementation in Australia.Entities:
Keywords: Community pharmacy services; barriers; determinants of practice; facilitators; health service research; qualitative meta-synthesis
Mesh:
Year: 2017 PMID: 28877940 PMCID: PMC5588935 DOI: 10.1136/bmjopen-2016-015471
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Levels where elements that can influence the implementation of community pharmacy services can exist (adapted from McLeroy et al 28)
| Individual patient | Influential elements related to the personal characteristics and ideas concerning individual patients (ie, individual determinants), such as their knowledge, beliefs and skills, that can affect their utilisation of community pharmacy services. |
| Interpersonal | Influential elements related to the healthcare providers and non-healthcare personnel (ie, individual determinants) who are involved with the community pharmacy service and with whom patients associate (eg, family, friends, pharmacists, pharmacy assistants, GPs and nurses) and the formal and informal relationships between patients and healthcare professionals and healthcare professionals with other healthcare professionals. |
| Organisational | Influential elements related to characteristics of the community pharmacy setting and their decision processes, and attributes of the community pharmacy service that can influence the success of implementation. |
| Community and system | Influential elements related to the larger society (ie, environmental determinants), which consists of collectives of people in a geographical location, the relationships between organisations, the political players in the system and the rules, regulations and policies that have the power to control and/or influence the implementation of services. |
Figure 1PRISMA flow diagram. PRISMA, Preferred Reporting Items for Systematic Review and Meta-Analysis.
General description of the articles included in the qualitative meta-synthesis
| Study | Description of participants | Service explored/assessed topic | Method | |||
| (n) | Pt | N | GP | |||
| McMillan | Patients with a chronic condition, diverse culture and socioeconomic background from three geographical locations in Queensland (Logan-Beaudesert and Mount Isa), New South Wales (Northern Rivers) and Western Australia (Greater Perth) (n=89) | X | Disease management and medication management (ie, chronic management service) | SSI | ||
| Rieck and | GPs working in practices in low, medium or high socioeconomic status suburbs across Perth (Western Australia) (n=22) | X | Disease management (ie, chronic disease management service) and interprofessional collaboration | SSI | ||
| Barbara and Krass | Patients who are immigrants of Maltese ethnicity, residing in Australia, with a confirmed diagnosis of T2DM, >50 years of age, able to adequately communicate verbally in English or Maltese, located in Sydney (n=24) | X | Disease management and medication management (ie, diabetes self-management service) | SSI | ||
| Bereznicki | Patients (n=6) and GPs (n=10) previously involved in a community pharmacy-based asthma intervention in Tasmania | X | X | Disease management (ie, asthma management service) | SSI | |
| Cvetkovski | Patients >18 years of age with a diagnosis of asthma (n=10) and GPs in small rural centres (n=8) from different locations based on the Australian Standard Geographical Classification | X | X | Disease management (ie, asthma management service) | SSI | |
| Saba | Patients >18 years of age, English speaking, current smoker, medical diagnosis of asthma and/or any other condition alongside asthma in Sydney Central Business District and South Western suburbs (n=24) | X | Disease management (ie, smoking cessation service for patients with asthma) | SSI | ||
| Shoukry | Patients who had bought/hired/trialled a continuous positive airway pressure machine (or accessories) through their pharmacy in the previous 12 months in the greater Sydney region (n=20) | X | Disease management (ie, obstructive sleep apnoea services) | SSI | ||
| Um | GPs with large expertise in weight management (n=3) | X | Disease management (ie, weight management service) | SSI | ||
| Snell and White | Patients >18 years of age, English speaking, enrolled in a specific weight loss programme for >2 weeks from different urban and regional suburbs in Sydney (n=20) | X | Disease management (ie, weight management service) | SSI | ||
| Maher | Women who have at least one child <5 years old are able to read and speak English from different locations based on Australian Standard Geographical Classification (n=28) | X | Condition management (ie, maternal nutrition service) | SSI | ||
| Mey | Patients living independently, experiencing a mild to moderate mental illness (and carers) in Queensland, New South Wales and Western Australia (n=74*) | X | Medication management (ie, service for patients with mental health conditions) | FG/SSI | ||
| Hattingh | Patients with a mental health condition (and carers) (n=74*) and healthcare professionals (n=13) located in urban, regional, rural and remote regions in Queensland, New South Wales and Western Australia | X | Disease management (ie, service for patients with mental health conditions) | FG/SSI | ||
| Clark | Refugee women (n=38)**† | X | Medication management (ie, primary healthcare service) | FG | ||
| O’Connor | Palliative care nurses working in community-based palliative care, residential aged care adopting a palliative approach or working in a dedicated hospice or palliative care unit in a hospital (n=44) and practising GPs (n=10) in Australian metropolitan and regional areas | X | X | Disease management and medication management (ie, services to community-based palliative care patients) | FG/SSI | |
| Carter | Patients who are English, Mandarin or Arabic speaking, who had received a home medicines review service within the last 6 months or had not received such a service but were eligible for it in metropolitan or rural areas in Australia (n=80) | X | Medication management (ie, home medicines review) | FG | ||
| Lee | Patients living in retirement villages in Victoria who were using prescribed medicines (n=25); GPs (n=9) and nurses (n=1) with experience with home medicines review services and/or providing care to retirement village residents. | X | X | X | Medication management (ie, home medicines review) | FG/SSI |
| White and Klinner | Patients of Chinese or Vietnamese origin who had never received a home medicines review service but were eligible for it in two suburban areas in Sydney (n=17) | X | Medication management (ie, home medicines review) | FG | ||
| White | Patients who had received a home medicines review service in the past 6 months or who had never received such a service but were eligible for it in New South Wales, Victoria, Queensland and South Australia (n=77) | X | Medication management (ie, home medicines review) | FG | ||
| Dhillon | GPs practising in metropolitan medical centres in Perth (n=24) | X | Medication management (ie, home medicines review) | SSI | ||
| Swain and Barclay | Patients taking multiple medications, with a reasonable understanding of English and linked to an Aboriginal Health Service in urban, regional, rural and remote settings in Queensland, Northern Territory, South Australia, New South Wales and Victoria (n=101) | X | Medication management (ie, service aimed at enhance the quality use of medicines) | FG | ||
| Du Pasquier and Aslani | Patients >18 years of age, fluent in English, taking one prescription medication on a daily basis in Sydney (n=22) | X | Medication management (ie, adherence support service) | SSI | ||
| Gilmartin | Nurses who worked at residential aged care facilities and used dose administration aids in Victoria (n=5) | X | Medication management (ie, dose administration aids service) | FG | ||
| Bui | Nurses working in public, opioid substitution therapy clinics in New South Wales (n=9) | X | Disease management (ie, opioid substitution therapy services) | SSI | ||
| Van | GPs practising in private/medical/specialised settings in rural/suburb/city areas in Sydney (n=23) | X | Interprofessional collaboration in the context of disease management and medication management (ie, professional pharmacy services) | SSI | ||
| Van | GPs in metropolitan and rural areas in New South Wales (n=15)† | X | Interprofessional collaboration in the context of a disease management (ie, diabetes medication assistance service) and medication management (ie, home medicines review service) | SSI | ||
| Dey | GPs working in Western Sydney (n=7)† | X | Interprofessional collaboration in the context of disease management (ie, asthma management services) | SSI | ||
| Chong | GPs (n=4) and nurses (n=7) working with mental health consumers in a healthcare setting in New South Wales | X | X | Interprofessional collaboration in the context of disease management (ie, mental health services) | SSI | |
| Cheong | Patients >18 years of age, English speaking, with a diagnosis of asthma in inner-west Sydney metropolitan region (n=16) | X | Interprofessional collaboration in the context of disease management (ie, asthma management service) | SSI | ||
| Bajramovic | Patients >18 years of age, taking at least one medication (n=7) and GPs (n=10) in Brisbane | X | X | Medication management (ie, concordance based healthcare services) | FG/SSI | |
*Total number of patients and carers. Opinions of carers were clearly differentiated in the article and excluded from this review.
†No further description of participants was provided in the paper.
FG, focus group; GP, general practitioner; N, nurse; Pt, patient; SSI, semistructured interview; T2DM, type 2 diabetes mellitus.
Elements that can hinder (ie, barrier) or enable (ie, facilitator) the implementation of CPSs as identified by patients, general practitioners and nurses
| Effect on implementation and source of information (ie, stakeholder) | ||
| Barrier* | Facilitator† | |
|
| ||
| 1. Patients’ real or perceived need for healthcare (according to patients’ individual concerns, understanding or perception of their health problems). | Pt | Pt |
| 2. Patients’ awareness of the availability of CPS | Pt | |
| 3. Patient personal desire or preference for CPSs | Pt | |
| 4. Patients’ understanding, perceptions and expectations of their own role in the CPS | Pt | Pt |
| 5. Patients’ understanding, perceptions and expectations of the role of community pharmacists in healthcare | Pt | Pt |
| 6. Patients’ understanding, perceptions and expectations of the role of the GP associated to the CPS | Pt | |
| 7. Patients’ understanding, perceptions and expectations of collaboration between healthcare professionals | Pt | Pt |
| 8. Patients’ availability, time to participate in CPSs | Pt | Pt |
| 9. Patients’ previous/background experiences with CPSs and multidisciplinary care | Pt | Pt |
| 10. Patient abilities; that is, to follow the procedures of the CPS or to self-manage their health problems | Pt | Pt |
| 11. Patients’ satisfaction with the delivered CPSs and multidisciplinary care | Pt | |
| 12. Patients’ motivation towards CPSs | Pt | Pt |
| 13. Patients’ level of emotional intelligence; that is, ability to cope with negative experiences. | Pt | Pt |
| 14. Patients’ language, communication and cultural issues | Pt | |
|
| ||
|
| ||
|
| ||
| 15. Knowledge, expertise, clinical and non-clinical skills (eg, cultural competency) to adequately provide CPSs | Pt | Pt18*, 20, 38, 40, 41*, 42, 44, 48; GP |
| 16. Communication skills, including the capacity to speak other languages | Pt | Pt |
| 17. Humanistic attributes (eg, being respectful, caring, non-judgemental, friendly, empathetic, supportive and approachable) | Pt | Pt |
| 18. Willingness, interest and motivation to provide CPSs and/or participate in multidisciplinary collaboration | N | Pt |
|
| ||
| 19. Technical knowledge (eg, about a product) | Pt | Pt |
| 20. Communication skills | Pt | Pt |
| 21. Humanistic attributes | Pt | |
| 22. Ability to work professionally (eg, uphold patient confidentiality) | Pt | |
| 23. Experience working in the pharmacy | Pt | Pt |
|
| ||
| 24. Understanding, perceptions and expectations of their individual role with regard CPSs | GP | |
| 25. Understanding, perceptions and expectations of pharmacist’s capabilities and role in healthcare | GP | GP |
| 26. Awareness of the availability of CPS | GP | |
| 27. Willingness, interest, motivation to collaborate with CPSs | GP | GP |
|
| ||
| 28. Understanding, perceptions and expectations of their individual role within, or in regards to, CPSs | N | |
| 29. Knowledge and skills to adequately participate in the delivery of CPS | N | N19* |
| 30. Attitude towards other healthcare professionals and their roles | N | |
| 31. Willingness, interest and motivation to collaborate with CPSs | N | N |
|
| ||
| 32. Influence of friends and family on patients utilising CPSs (ie, they may provide support, affect patient’s adherence or patient’s enthusiasm with CPSs) | Pt | Pt17*, 35*, 41 |
| 33. Previous relationship between the patient and the pharmacist and its nature (eg, trusting relationship) | Pt | Pt |
| 34. Collaborative relationships between the pharmacist and other healthcare providers (eg, GPs) and their nature | Pt | Pt |
| 35. Communication channels and modes between pharmacists and other healthcare providers (eg, GPs) | N | Pt |
| 36. Existence of referral mechanisms between healthcare professionals, including also those between pharmacy support staff and pharmacists (ie, care coordination and transition) | Pt | Pt |
| 37. Consistency in the information provided by the pharmacist with regards to the GP’s recommendations | GP | GP |
| 38. Availability of multidisciplinary education, training and meetings for pharmacists and GPs that enhance integrated, collaborative care | Pt52*, 56*; N | |
|
| ||
|
| ||
| 39. Accessibility of the pharmacy setting (eg, convenient location, colocation, no appointments required and opening hours) | Pt | Pt17, 33, 35, 37, 38, 40, 41, 56*, 57; N |
| 40. Structural characteristics of the pharmacy setting, that is, size, provision of counselling rooms, use of visual space for posters and child-friendly area | Pt | Pt40, 41, 43* |
| 41. Privacy of the setting, including the availability of a private consultation area and limited involvement of multiple staff members who would be aware of the patients’ personal matters | Pt | Pt |
| 42. Availability of suitable material resources to support the service (eg, educational material for patients, medical devices, patient data management system and so on) | Pt | |
| 43. Sufficient qualified staff to perform CPS | Pt | Pt |
| 44. Organisation of the pharmacist’s workload and time to deliver CPSs | Pt | Pt |
| 45. Organisational commitment to implement a CPS | Pt | |
| 46. Promotion of the CPS to facilitate its uptake | Pt33*, 35*, 47; GP | |
|
| ||
| 47. Extent to which the CPS meets and is tailored to fit individual patient’s needs or fills existing gaps in healthcare practice (this enhances the value of the service for patients and healthcare professionals) | Pt | Pt |
| 48. Quality of the CPS (eg, validity, accuracy of the materials and tools used, CPSs provided in a timely manner, provision of both verbal and written information, professional advice and education and so on) | Pt | Pt |
| 49. Complexity of the CPS for use by healthcare professionals | GP | |
| 50. Extent to which CPSs provide ongoing support, follow-up and feedback to patients | GP | Pt |
| 51. Flexibility to use different communication channels (eg, telephone and website) to interact with patients and healthcare providers | Pt38, 40, 43* | |
| 52. Consistency in the community pharmacist delivering the CPS | Pt, | |
| 53. Involvement of other healthcare providers in delivering the CPS | Pt | |
| 54. Costs and duration of the CPS consultation for the patient | Pt | Pt |
|
| ||
| 55. General consumer education about healthcare; promotion of CPS by the media | Pt | Pt |
| 56. Collaboration, influences, conflicts between GP and pharmacist professional bodies | GP34* | |
| 57. Organisation of GPs’ workload and time to collaborate with CPSs | GP | |
| 58. Complexity of system-level administrative processes (eg, tedious paperwork) associated to the delivery of CPS; that is, complying with the requirements of the department of health | GP | |
| 59. Availability of an electronic system for sharing information | Pt | Pt17*, 57; N19*; GP17, 20*, 36*, 50, 52*, 53 |
| 60. Presence of agreed healthcare protocols, regulations, rules and policies to facilitate the delivery of CPSs | Pt | Pt |
| 61. Limits on the healthcare budget; that is, funding allocated to support CPS delivery | GP | Pt44, 56*; GP |
| 62. Availability of financial incentives for service provision and inter-professional collaboration | Pt56*; N51* | |
| 63. Organisation of the healthcare system | Pt | |
*Barrier: the element was mentioned to act as a BARRIER or hinder to the implementation of CPSs.
†Facilitator: the element was mentioned to act as a FACILITATOR or enabler to the implementation of CPSs.
(*) This element was reported as a potential strategy to overcome a barrier (ie, facilitator).
CPSs, community pharmacy services; GP, general practitioner; N, nurse; Pt, patient.